Investor Presentaiton slide image

Investor Presentaiton

Phase 2 Clinical Trial - Comparatively High-Risk, Poor Prognosis Population Disease Burden Significantly Higher in Both Any-Line and First-Line MUM Population+ * IDE196-001 Phase 2* Darovasertib + Crizotinib Tebentasfusp First-Line Phase 3# Baseline Characteristics Any-Line n=63 (%) First-Line n=20 (%) < 65 35 (56) 10 (50) Tebe Arm n=252 (%) 64 Median Control Arm^ n=126 66 Median Age ≥65 28 (44) 10 (50) F 32 (51) 9 (45) 124 (49) 64 (51) Sex M 31 (49) 11 (55) 128 (51) 62 (49) 0 43 (68) 14 (70) 192 (76) 85 (67) ECOG PS 1 20 (32) 6 (30) 49 (19) 31 (25) Normal 25 (40) 10 (50) Baseline LDH >ULN 38 (60) 10 (50) 90 (36) 46 (37) ≤3.0 cm 22 (35) 8 (40) 139 (55) 70 (56) Largest metastatic lesion 3.1 to 8.0 cm 35 (56) 9 (45) 92 (37) 46 (37) ≥ 8.1 cm 6 (10) 3 (15) 21 (8) Location of metastases Hepatic Only Extrahepatic Only 20 (32) 10 (50) 131 (52) 3 (5) 0 9 (4) Hepatic and Extrahepatic 40 (64) 10 (50) 11 + Cross-trial comparisons are not based on head-to-head studies and are presented for informational purposes; no direct comparisons are being made *IDEAYA Data as of March 08, 2023 (based on preliminary analysis of unlocked database by investigator review) # N Engl J Med 2021; 385:1196-1206; ECOG data missing in Tebentafusp and Control arm of 4% and 7% respectively ^Investigator Choice distribution in the control group: 103 (82%) received pembrolizumab, 16 (13%) received ipilimumab, and 7 (6%) received dacarbazine. 111 (44) 10 (8) 59 (47) 10 (8) 55 (44) IDEA A BIOSCIENCES
View entire presentation